| Drug Name | Sprycel (Dasatinib) |
|---|---|
| Drug Class |
Anticancer
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Hematology
Oncology
|
| Risk |
Risk of (PAH) Pulmonary Arterial Hypertension. The association of BCR-ABL targeting Tyrosine Kinase inhibitors (TKIs) including SPRYCEL® (dasatinib) with the risk of hepatitis B virus reactivation . |
| Dear Healthcare provider letter DHPC |
|